Pre-made Nidanilimab benchmark antibody ( Whole mAb, anti-IL1RAP therapeutic antibody, Anti-C3orf13/IL-1RAcP/IL1R3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nidanilimab biosimilar, Whole mAb, Anti-IL1RAP Antibody: Anti-C3orf13/IL-1RAcP/IL1R3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-375-1mg	1mg	3090
GMP-Bios-ab-375-10mg	10mg	Inquiry
GMP-Bios-ab-375-100mg	100mg	Inquiry
GMP-Bios-ab-375-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nidanilimab biosimilar, Whole mAb, Anti-IL1RAP Antibody: Anti-C3orf13/IL-1RAcP/IL1R3 therapeutic antibody
INN Name	Nidanilimab
Target	IL1RAP
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Lund University;Cantargia
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Pancreatic cancer;Solid tumours
Conditions Discontinued	na
Development Tech	na